{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:45:23Z","timestamp":1767987923127,"version":"3.49.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The management of recurrent WHO grades II\u2013III (rGII\u2013III) glioma is not well established. This study describes the clinical outcomes in patients who received bevacizumab as rescue treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective study, the main inclusion criteria were as follows: adult patients with histologicaly proved rGII\u2013III glioma according 2016 WHO classification treated with bevacizumab from 2011 to 2019, T1 contrast enhancement on MRI. Efficacy was assessed using the high-grade glioma 2017 Response Assessment in Neuro-Oncology criteria. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan\u2013Meier method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty-one patients were included (M\/F ratio: 1.7, median age at diagnosis: 38 years) among whom 46 (56.8%) had an initial diagnosis of grade II glioma. Previous treatments included at least one surgical intervention, radiotherapy (98.8%), and \u2265 2 chemotherapy lines (64.2%). After bevacizumab initiation, partial response, stable disease, and progressive disease were observed in 27.2%, 22.2%, and 50.6% of patients. The median PFS and OS were 4.9 months (95% confidence interval [CI] 3.7\u20136.1) and 7.6 months (95% CI 5.5\u20139.9). Bevacizumab severe toxicity occurred in 12.3%. Twenty-four (29.6%) patients discontinued bevacizumab without radiological progression. Oligodendroglioma and age \u2265 38 years at diagnosis were more frequent in this subgroup (odds ratio = 0.24, 95% CI 0.07\u20130.84, <jats:italic>p<\/jats:italic> = 0.023 and 0.36, 95% CI 0.13\u20130.99, <jats:italic>p<\/jats:italic> = 0.042). Ten of these 24 patients were alive at 12 months and two patients at 8 years after bevacizumab initiation, without any subsequent treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Bevacizumab can be an option for heavily pretreated patients with rGII\u2013III glioma with contrast enhancement. In our study, bevacizumab displayed prolonged activity in a subgroup of patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1212714","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T09:14:36Z","timestamp":1689671676000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Bevacizumab in recurrent WHO grades II\u2013III glioma"],"prefix":"10.3389","volume":"13","author":[{"given":"Soufyan","family":"Annakib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Rigau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Darlix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Goz\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugues","family":"Duffau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Bauchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Jarlier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nec.2018.08.010","article-title":"Epidemiology and molecular epidemiology","volume":"30","author":"Bauchet","year":"2019","journal-title":"Neurosurg Clinics North America"},{"key":"B2","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united states in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro-Oncology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-014-1585-0","article-title":"Significant heterogeneity in the geographical distribution of diffuse grade II\/III gliomas in France","volume":"120","author":"Darlix","year":"2014","journal-title":"J Neurooncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou153","article-title":"New concepts in the management of diffuse low-grade glioma: proposal of a multistage and individualized therapeutic approach","volume":"17","author":"Duffau","year":"2014","journal-title":"Neuro-Oncology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-020-03677-4","article-title":"Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV: a single-institution case series and review","volume":"152","author":"Lee","year":"2021","journal-title":"J Neurooncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02929","article-title":"Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma","volume":"41","author":"Hervey-Jumper","year":"2023","journal-title":"JCO"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2175","article-title":"Angiogenesis in brain tumours","volume":"8","author":"Jain","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2309","article-title":"Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma","volume":"13","author":"Vredenburgh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"JCO"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"JCO"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.2013.31.18_suppl.1","article-title":"RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM)","volume":"31","author":"Gilbert","year":"2013","journal-title":"JCO"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30362-0","article-title":"Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p\/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial","volume":"19","author":"van den Bent","year":"2018","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/801306","article-title":"An observational study of the first experience with bevacizumab for the treatment of patients with recurrent high-grade glioma in two Belgian university hospitals","volume":"2012","author":"Huylebrouck","year":"2012","journal-title":"J Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-008-9722-2","article-title":"Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma","volume":"91","author":"Chamberlain","year":"2009","journal-title":"J Neurooncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802537924","article-title":"Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours","volume":"48","author":"Poulsen","year":"2009","journal-title":"Acta Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000343811","article-title":"Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas","volume":"69","author":"Seystahl","year":"2013","journal-title":"Eur Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2217\/cns.15.27","article-title":"Bevacizumab and other novel therapies for recurrent oligodendroglial tumors","volume":"4","author":"Grimm","year":"2015","journal-title":"CNS Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3171\/2008.4.17492","article-title":"Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival: clinical article","volume":"110","author":"Narayana","year":"2009","journal-title":"J Neurosurg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.2014.945436","article-title":"Predictive biomarkers investigated in glioblastoma","volume":"14","author":"Tabouret","year":"2014","journal-title":"Expert Rev Mol Diagnostics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq099","article-title":"Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma","volume":"12","author":"Sathornsumetee","year":"2010","journal-title":"Neuro-Oncology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.5005","article-title":"Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial","volume":"33","author":"Sandmann","year":"2015","journal-title":"JCO"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-021-01305-4","article-title":"Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study","volume":"10","author":"Jiguet-Jiglaire","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov094","article-title":"MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma","volume":"17","author":"Tabouret","year":"2015","journal-title":"Neuro Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2018.1430818","article-title":"Biomarkers in recurrent grade III glioma patients treated with bevacizumab and irinotecan","volume":"36","author":"Toft","year":"2018","journal-title":"Cancer Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.3726","article-title":"Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of","volume":"32","author":"Cairncross","year":"2014","journal-title":"IDH JCO"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos206","article-title":"Personalized care in neuro-oncology coming of age: why we need MGMT and 1p\/19q testing for malignant glioma patients in clinical practice","volume":"14","author":"Weller","year":"2012","journal-title":"Neuro-Oncology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1225-0","article-title":"Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival","volume":"115","author":"Chen","year":"2013","journal-title":"J Neurooncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"CNS35","DOI":"10.2217\/cns-2019-0007","article-title":"Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series","volume":"8","author":"Liu","year":"2019","journal-title":"CNS Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1156-z","article-title":"ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis","volume":"126","author":"Wiestler","year":"2013","journal-title":"Acta Neuropathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1370-3","article-title":"ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an \u201cintegrated\u201d diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma","volume":"129","author":"Reuss","year":"2015","journal-title":"Acta Neuropathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/his.12743","article-title":"Combined ATRX\/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas","volume":"68","author":"Hewer","year":"2016","journal-title":"Histopathology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.689","article-title":"Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma","volume":"3","author":"Kannan","year":"2012","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"JCO"},{"key":"B40","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/onco.13765","article-title":"TEMOBIC: phase II trial of neoadjuvant chemotherapy for unresectable anaplastic gliomas: an ANOCEF study","volume":"26","author":"Tabouret","year":"2021","journal-title":"Oncologist"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/65711810","article-title":"Conventional MRI evaluation of gliomas","volume":"84","author":"Upadhyay","year":"2011","journal-title":"BJR"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4920","article-title":"IDH1\/2 mutation status combined with ki-67 labeling index defines distinct prognostic groups in glioma","volume":"6","author":"Zeng","year":"2015","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cas.13889","article-title":"Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab","volume":"110","author":"Tamura","year":"2019","journal-title":"Cancer Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107826","article-title":"Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy","volume":"97","author":"Lin","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1158\/0008-5472.CAN-19-1577","article-title":"Dysregulation of glutamate transport enhances treg function that promotes VEGF blockade resistance in glioblastoma","volume":"80","author":"Long","year":"2020","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12183","article-title":"Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges","volume":"41","author":"Li","year":"2021","journal-title":"Cancer Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02317-9","article-title":"Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients","volume":"68","author":"Quillien","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1281","article-title":"Gene expression profile identifies tyrosine kinase c-met as a targetable mediator of antiangiogenic therapy resistance","volume":"19","author":"Jahangiri","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10014-017-0284-x","article-title":"Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response","volume":"34","author":"Tamura","year":"2017","journal-title":"Brain Tumor Pathol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4103\/jcar.jcar_17_21","article-title":"Molecular classification and stratification of adult diffuse gliomas: a tertiary care center study","volume":"20","author":"Anand","year":"2021","journal-title":"J Carcinog"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2011.0037","article-title":"Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis","volume":"9","author":"Wong","year":"2011","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1212714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T09:14:38Z","timestamp":1689671678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1212714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":52,"alternative-id":["10.3389\/fonc.2023.1212714"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1212714","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"article-number":"1212714"}}